Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.
Tianhong Li, MD, PhD
Advertisement
Articles by Tianhong Li, MD, PhD
Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy
Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene
Dr. Tianhong Li from UC Davis Cancer Center Discusses the PROFILE Crizotinib Clinical Trials
Dr. Tianhong (Tina) Li from UC Davic Cancer Center Discusses ALK Gene Mutation Tests
Advertisement
Latest Updated Articles
Dr. Li Discusses the PROFILE Crizotinib Clinical TrialsPublished: September 1st 2011 | Updated:
Dr. Li Discusses the EML4-ALK Fusion GenePublished: September 9th 2011 | Updated:
Dr. Li Describes the Future of Lung Cancer TherapyPublished: September 19th 2011 | Updated:
Dr. Li Reviews Afatinib Data From the LUX-Lung 3 TrialPublished: January 17th 2013 | Updated:
Dr. Li Discusses ALK Gene Mutation TestsPublished: August 29th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5